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Abstract The zinc finger protein A20 is encoded by an
immediate early response gene whose expression is induced by
different inflammatory stimuli, including interleukin-1 (IL-1).
Gene induction by IL-1 is mediated by activation of the
transcription factor NF-UB, and requires the signal adapter
protein TRAF6. The latter interacts with the NF-UB-inducing
kinase NIK, which is believed to be part of the IUB kinase
complex. Expression of A20 potently inhibits IL-1-induced NF-
UB activation by an unknown mechanism. Inhibition of IL-1-
induced NF-UB activation was found to be mediated by the C-
terminal zinc finger-containing domain of A20. More impor-
tantly, we present evidence that A20 interferes with IL-1-induced
NF-UB activation at the level of TRAF6, upstream of NIK.
Moreover, A20 was shown to directly interact with TRAF6.
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1. Introduction
The transcription factor NF-UB resides in an inactive state
as a cytosolic protein and is activated by di¡erent proin£am-
matory cytokines including interleukin-1 (IL-1). IL-1 signal-
ling is initiated by the formation of the high-a⁄nity complex
composed of IL-1, IL-1 receptor (IL-1R) and IL-1R accessory
protein (IL-1RAcP). This is followed by the recruitment of the
adapter protein MyD88 and the IL-1 receptor-associated kin-
ase (IRAK) to the receptor complex [1^4]. Then IRAK inter-
acts with TRAF6, which ¢nally results in NF-UB activation
[5]. TRAF6 is a member of a new family of signalling proteins
that is characterised by the presence of a conserved TRAF
domain of approximately 230 amino acids in the C-terminal
portion, and multiple zinc ¢nger motifs within the N-terminal
half. The TRAF domain mediates homotypic and heterotypic
interactions and is also involved in binding to other signalling
molecules including the NF-UB-inducing kinase NIK [6]. The
latter then interacts with and activates the IUB kinases IKKK
and IKKL which are part of a multiprotein IUB kinase com-
plex, leading to the phosphorylation, ubiquitination and sub-
sequent degradation of the NF-UB inhibitory subunit IUB
[7^9]. This allows NF-UB translocation to the nucleus and
activation of the transcription of several genes involved in
in£ammation, immune responses, lymphoid di¡erentiation,
growth control and development.
Previously, the cytokine-inducible zinc ¢nger protein A20
was shown to block IL-1-mediated NF-UB activation by an
unknown mechanism [10]. We could demonstrate that inter-
action of A20 with 14-3-3 proteins is not required for its NF-
UB-inhibiting activity [11]. To better understand how and at
what level A20 interferes with IL-1-induced signal transduc-
tion leading to NF-UB activation, we made use of the ability
to activate NF-UB activation by overexpression of speci¢c
signalling proteins involved in IL-1-induced NF-UB activa-
tion. Our results clearly demonstrate that A20 blocks IL-1-
induced NF-UB activation upstream of NIK, most likely via a
direct interaction with TRAF6.
2. Materials and methods
2.1. Cell lines and reagents
Human embryonic kidney cells (293T) were a kind gift of Dr M.
Hall (Department of Biochemistry, University of Birmingham, UK).
These cells were cultured in DMEM supplemented with 10% FCS,
0.4 mM sodium pyruvate and antibiotics.
Recombinant human tumour necrosis factor (TNF) was expressed
in Escherichia coli and had a speci¢c biological activity of 8.8U106
IU/mg puri¢ed protein, as determined with the International Standard
(code 88/532) (National Institute for Biological Standards and Con-
trol, Potters Bar, UK). Recombinant murine IL-1L was produced by
E. coli and had a speci¢c activity of 3.65U108 IU/mg puri¢ed protein,
as determined with the International Standard (code 93/668) (Nation-
al Institute for Biological Standards and Control, Potters Bar, UK).
Anti-Flag tag antibody was purchased from Eastman Kodak Com-
pany (New Haven, CT, USA), polyclonal anti-TRAF2 antibody from
Immunotech (Marseille, France), polyclonal anti-GFP from Clontech
(Palo Alto, CA, USA), monoclonal anti-E-tag horseradish peroxidase
linked from Pharmacia Biotech (Uppsala, Sweden), protein A on Tris-
acryl beads from Pierce Chemicals (Rockford, IL, USA), and anti-
rabbit Ig antibody as well as ECL Western blot detection kit from
Amersham Life Sciences (Amersham, UK).
2.2. Expression plasmids
The plasmid pCAGGS-GFP was made by inserting the GFP-encod-
ing cDNA including a multiple cloning site from the pGFP-CI plas-
mid (Clontech, Palo Alto, CA) in the EcoRI-MscI sites of the eukary-
otic expression plasmid pCAGGS [12]. In the GFP-cDNA a S65T
mutation was inserted to enhance £uorescence. In the SmaI site of
the multicloning site inserted in the GFP-cDNA, a blunted NcoI-
EcoRI fragment of mA20 was cloned in frame with the C-terminus
of GFP, resulting in the vector pCAGGS-GFP/A20. Also the NcoI-
FspI fragment of A20 encoding the N-terminal amino acids (1^369)
and the FspI-EcoRI fragment encoding the C-terminal amino acids
(370^775) were cloned in frame with GFP, resulting in the plasmids
pCAGGS-GFP/A20(ZF3) and pCAGGS-GFP/A20(ZF+), respec-
tively.
The plasmid pNFconluc contains the luciferase reporter gene driven
by a minimal NF-UB-responsive promoter and was a kind gift of Dr
A. Israel (Institut Pasteur, Paris, France) [13]. The L-galactosidase-
encoding plasmid pUT651 was obtained from Cayla (Toulouse,
France). Expression plasmids for TRAF1, TRAF2, Flag-tagged
TRAF6 (gifts from Dr D. Goeddel, Tularik, San Francisco, CA,
USA) and NIK (gift from Dr D. Wallach, Weizmann Institute of
Science, Rehovot, Israel) have been described previously [5,6,14].
2.3. NF-UB reporter gene assay
293T cells were grown in 6-well plates and transfected by DNA
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calcium phosphate precipitation [15] with 100 ng pUT651, 100 ng
pNFconluc, 700 ng empty vector pCAGGS and 100 ng pCAGGS-
GFP or pCAGGS-GFP/A20. After transfection cells were seeded in
24-well plates. Another 24 h later cells were either stimulated with
1000 IU/ml TNF or 7000 IU/ml IL-1 for 6 h or left untreated, fol-
lowed by lysis of the cells in Tris-phosphate (25 mM pH 7.8), DTT
(2 mM), CDTA (2 mM), glycerol (10%) and Triton X-100 (1%).
Luciferase and L-galactosidase activities were measured as described
previously [11].
When NF-UB activation by overexpression of TRAF6 and NIK
was analysed, cells were immediately seeded in 24-well plates and
transfected with 20 ng pNFconluc, 20 ng pUT651, 20 ng plasmids
encoding TRAF6 or NIK, 100 ng pCAGGS-GFP or pCAGGS-
GFP/A20 and 40 ng empty vector. 24 h after transfection cells were
lysed and processed as described above.
2.4. Coimmunoprecipitation and Western blotting
106 293T cells were grown in 10-cm Petri dishes and transiently
transfected with in total 5 Wg plasmid DNA using the DNA calcium
phosphate coprecipitation method as described [15]. 24 h after trans-
fection cells were lysed in Tris-HCl (20 mM pH 7.5), Triton X-100
(1%), NaCl (137 mM), MgCl2 (1.5 mM) and EGTA (1 mM). Immu-
noprecipitation was performed with polyclonal anti-TRAF2 antibody
or monoclonal anti-Flag tag antibody and binding to protein A Tris-
acryl beads. Beads were washed four times with lysis bu¡er and bind-
ing proteins were analysed by 10% SDS-PAGE and Western blotting
onto nitrocellulose membranes. Detection of coimmunoprecipitating
proteins was achieved with monoclonal anti-E tag antibody coupled
to horseradish peroxidase and an ECL Western blotting detection kit
according to the manufacturer’s instructions.
3. Results
3.1. A20 inhibits IL-1-induced NF-UB activation via its
C-terminal zinc ¢nger containing domain
The A20 protein consists of seven Cys2/Cys2 zinc ¢ngers in
the C-terminal half of the molecule [16]. By the use of N- and
C-terminal deletion mutants, the C-terminal zinc ¢nger-con-
taining domain of A20 has previously already been implicated
in the inhibitory e¡ect of A20 on TNF-induced NF-UB acti-
vation [17]. To investigate if the same domain of A20 also
mediates inhibition of the IL-1 signal transduction pathway
to NF-UB, we transiently transfected 293T cells with an NF-
UB-dependent reporter gene and expression plasmids for A20,
its N-terminal (A20(ZF3)) or its C-terminal (A20(ZF+)) frag-
ments corresponding to amino acids 1^369 and 370^775, re-
spectively. In all cases A20 was fused to GFP which allows
detection via Western blotting. Transfected cells were treated
with TNF or IL-1 for 6 h and analysed for NF-UB activation
by measuring the NF-UB-responsive expression of the lucifer-
ase reporter gene. NF-UB activation by TNF or IL-1 was
maximal at concentrations of 1000 IU/ml and 7000 IU/ml,
respectively, but could already be obtained at a TNF or IL-
1 concentration as low as 50 IU/ml (data not shown). As
expected, overexpression of the fusion protein GFP/A20 in
293T cells clearly prevented TNF-induced and IL-1-induced
NF-UB activation whereas overexpression of GFP as such had
no e¡ect (Fig. 1). When only the C-terminal part of A20 was
expressed (GFP/A20(ZF+)), NF-UB activation was equally
well repressed. In contrast, overexpression of the N-terminal
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Fig. 1. E¡ect of overexpression of wild-type or N- and C-terminal
deletion mutants of A20 on NF-UB activation induced by TNF and
IL-1. 293T cells were transiently transfected with an NF-UB-depend-
ent luciferase reporter gene (luc) and a L-galactosidase (gal) expres-
sion plasmid as described in Section 2. 24 h later, cells were stimu-
lated with TNF (1000 IU/ml) or IL-1 (7000 IU/ml) during 6 h. The
e¡ect of A20 was analysed by cotransfection of GFP/A20 or frag-
ments corresponding to the N-terminal (GFP/A20(ZF3)) or C-ter-
minal half (GFP/A20(ZF+)) of A20. GFP was cotransfected as a
negative control. Luciferase activity present in cell extracts was used
as a parameter for NF-UB activation, and is expressed as luc/gal to
normalise transfection e⁄ciencies. Data (n = 3) are from a represen-
tative experiment with standard deviations less than 10%.
Fig. 2. E¡ect of A20 overexpression on NF-UB activation induced
by overexpression of TRAF6 and NIK. Cells were transfected with
a TRAF6 or NIK expression plasmid, a L-galactosidase expression
plasmid and an NF-UB-dependent luciferase reporter gene. The ef-
fect of A20 was analysed by cotransfection with an expression plas-
mid for GFP/A20. Cotransfection with GFP served as a negative
control. Cells were lysed 24 h after transfection and analysed for lu-
ciferase (luc) and L-galactosidase (gal) activity. Results from a repre-
sentative experiment are expressed as luc/gal to correct for di¡eren-
ces in transfection e⁄ciency, and are mean values (n = 3) with
standard deviations less than 10%.
Fig. 3. Coimmunoprecipitation of A20 with TRAF6 and TRAF2/
TRAF1. 293T cells were transiently transfected with E-tagged A20
or an irrelevant E-tagged protein (p110 PITSLRE kinase) together
with Flag-tagged TRAF6 or a combination of TRAF2 and TRAF1.
Immunoprecipitation (upper panel) was performed with anti-Flag
tag antibody or anti-TRAF2 antibody, respectively, and coimmuno-
precipitating proteins were revealed by Western blot detection with
anti-E tag antibody. To control expression levels of E-tagged A20
and the irrelevant protein, 10 Wl total cell lysates were subjected to
10% SDS-PAGE and immunoblotted with anti-E-tag antibody (low-
er panel).
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part of A20 (GFP/A20(ZF3)) had no e¡ect at all on both
TNF-induced and IL-1-induced NF-UB activation. Western
blotting with anti-GFP antibodies revealed that A20 and its
N- and C-terminal deletion mutants were in all cases equally
well expressed (data not shown). These results demonstrate
that upon overexpression the zinc ¢nger-containing domain
of A20 is su⁄cient for inhibition of TNF-induced as well as
IL-1-induced NF-UB activation.
3.2. A20 inhibits NF-UB upstream of NIK
As already mentioned in Section 1, the mitogen-activated
protein kinase kinase kinase NIK, which interacts with all
TRAF proteins, has been placed downstream of TRAF6 in
the IL-1-initiated NF-UB signalling pathway [6]. Overexpres-
sion of TRAF6 or NIK is su⁄cient to induce NF-UB activa-
tion. This allowed us to investigate at which point in the IL-1-
induced signalling pathway A20 could prevent NF-UB activa-
tion. Therefore, 293T cells were transiently transfected with
TRAF6 or NIK in combination with the expression plasmids
of GFP or GFP/A20 and an NF-UB-responsive reporter plas-
mid. NF-UB-dependent reporter gene expression was meas-
ured after 24 h. As expected, GFP expression had no e¡ect
on TRAF6-induced or NIK-induced NF-UB activation (Fig.
2). In contrast, GFP/A20 strongly inhibited NF-UB activation
induced by overexpression of TRAF6. Interestingly, GFP/A20
was not able to block NIK-induced NF-UB activation. These
results clearly indicate that A20 interferes upstream of NIK in
the IL-1 signal transduction pathway to NF-UB, presumably
at the level of TRAF6 itself.
3.3. A20 interacts with TRAF6
To further substantiate our hypothesis that A20 prevents
IL-1-induced NF-UB activation at the level of TRAF6, we
investigated if this inhibition could be mediated by a direct
interaction of A20 with TRAF6. In this respect, A20 has
previously already been shown to associate with the
TRAF1/TRAF2 complex in the TNF signalling pathway
[17]. Therefore 293T cells were transiently transfected with
expression plasmids encoding Flag-tagged TRAF6 and E-
tagged A20 or an E-tagged irrelevant protein which served
as a negative control. Cell lysates were immunoprecipitated
with a monoclonal anti-Flag tag antibody and then immuno-
blotted with anti-E-tag antibodies coupled with horseradish
peroxidase. This analysis demonstrated that A20 is able to
bind TRAF6 (Fig. 3) further indicating that A20 prevents
IL-1-induced NF-UB activation by directly interacting with
TRAF6. When we transfected TRAF2 and TRAF1 instead
of TRAF6 and made the immunoprecipitate with a polyclonal
anti-TRAF2 antibody, speci¢c interaction of A20 with
TRAF1/TRAF2 complex could be demonstrated as described
previously [17]. Therefore, A20 is likely to prevent TNF-in-
duced and IL-1-induced NF-UB activation at the level of
TRAF2 and TRAF6, respectively.
4. Discussion
The transcription factor NF-UB becomes activated in sev-
eral cell lines upon stimulation with the cytokines TNF and
IL-1, and is responsible for the transcription of many proin-
£ammatory genes. Its activation can be negatively regulated
by the NF-UB-associating protein IUB and by the zinc ¢nger
protein A20. Both are TNF- and IL-1-inducible proteins
whose expression is itself NF-UB-dependent, resulting in a
negative feedback regulation [18,19]. Whereas IUB inhibits
NF-UB activation by sequestration of latent NF-UB in an
inactive form in the cytoplasm, the mechanism by which
A20 abrogates NF-UB activation is still unknown.
Recently, the signal transduction pathways leading to NF-
UB activation by TNF and IL-1 have been largely elucidated.
Whereas the upstream proteins involved in these signalling
pathways are di¡erent in the case of TNF and IL-1, both
pathways converge at the NF-UB-inducing kinase NIK (Fig.
4) [6]. Our results show that A20 blocks IL-1-induced NF-UB
activation upstream of NIK, most likely at the level of
TRAF6. This is further suggested by our observation that
A20 can directly interact with TRAF6. Similarly, A20 has
been shown previously to interact with the TRAF1/TRAF2
complex, suggesting that the latter interaction might also be
involved in the A20-mediated inhibition of NF-UB activation
induced by TNF [17]. The C-terminal zinc ¢nger domain of
A20 was shown to be responsible for NF-UB inhibition. In
contrast, the N-terminal domain of A20 has been shown pre-
viously to interact with TRAF2 [17]. Although we did not
analyse whether this part of A20 also mediates its interaction
with TRAF6, these interactions would ¢t with a molecular
mechanism in which A20 is recruited to the NF-UB activation
cascade via its binding with TRAF2 or TRAF6. At this level
A20 could prevent NF-UB activation by disrupting essential
protein-protein interactions such TRAF2-RIP, TRAF6-
IRAK, TRAF2/6-TRAF2/6 or TRAF2/6-NIK. On the other
hand, A20 might interfere with the activation of NF-UB, by
preventing the TRAF-mediated activation of p38 MAP ki-
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Fig. 4. Overview of TNF- and IL-1-induced signalling pathways
leading to IUB degradation and activation of NF-UB. In the case of
TNF-RI, which is the main NF-UB-activating TNF receptor, signal-
ling starts with the recruitment of TRADD, which serves as an
adapter protein for two other components TRAF2 and RIP. These
also associate with each other, possibly stabilising the complex
[14,27,28]. IL-1R stimulation leads to the recruitment of MyD88
and IRAK to the IL-1 receptor complex. IRAK the associates with
TRAF6. TRAF2 and TRAF6 both bind with NIK which functions
as a direct activator of the IUB kinase complex. The IUB kinases of
this complex directly phosphorylate IUB, leading to its degradation
and NF-UB activation. Interaction of A20 with TRAF2/6 might be
involved in inhibition of TNF- and IL-1-induced NF-UB activation.
K. Heyninck, R. Beyaert/FEBS Letters 442 (1999) 147^150 149
nase, which has been shown previously to be involved in the
transactivation of NF-UB [20,21]. Recently, in some cell lines
TRAF2 has been shown to localise in the nucleus where it can
directly regulate transcription [22]. Since A20 is located in the
cytosol (own unpublished results, [23]), A20 could retain
TRAF2, and most likely also TRAF6, in the cytosol. Finally,
we cannot exclude that A20 might still interact with other
proteins which are responsible for the A20-mediated inhibi-
tion of NF-UB activation. In this context, we recently identi-
¢ed a number of A20-interacting proteins which are able to
inhibit NF-UB activation by TNF and IL-1 upon overexpres-
sion (unpublished results).
TRAF2 and TRAF6 not only link the TNF-R and IL-1R
to the NF-UB activation cascade, but have also been suggested
to be involved in the NF-UB activation by CD40, IL-18, the
human Toll receptor, and some other members of the TNF
and IL-1 receptor superfamily [24^26]. Therefore, binding of
A20 with TRAF2 and TRAF6 might provide a negative reg-
ulatory mechanism for NF-UB activation by many members
of the TNF and IL-1 receptor superfamily. However, in the
case of sepsis or chronic in£ammation, abundant secretion of
IL-1 or TNF may override the protective e¡ect of A20 leading
to the development of the disease. Therefore, reagents which
increase the cellular level of A20 might be useful tools in the
treatment of many in£ammatory diseases.
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